BC
MCID: BRS047
MIFTS: 97

Breast Cancer (BC)

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 57 11 42 75 73 12 53 41 2 14 63
Breast Carcinoma 11 42 73 28 53 5 14 16 71
Male Breast Cancer 11 19 41 14 75
Malignant Neoplasm of Breast 11 42 71 31
Breast Cancer, Familial 57 42 75 71
Breast Cancer, Susceptibility to 57 28 5
Breast Cancer, Early-Onset 57 28 5
Malignant Tumor of Breast 42 28 5
Carcinoma of Male Breast 28 5 71
Breast Cancer, Protection Against 57 5
Malignant Neoplasm of Male Breast 11 71
Invasive Ductal Breast Carcinoma 53 71
Breast Cancer, Lobular, Somatic 57 5
Breast Cancer, Invasive Ductal 57 5
Familial Cancer of Breast 28 5
Breast Cancer, Somatic 57 5
Male Breast Carcinoma 19 16
Breast Cancer, Male 57 19
Mammary Carcinoma 11 73
Mammary Cancer 11 42
Mammary Tumor 11 53
Breast Tumor 11 5
Infiltrating Ductular Carcinoma of Unspecified Site 33
Infiltrating Duct Carcinoma of Unspecified Site 33
Breast Cancer, Early-Onset, Susceptibility to 57
Invasive Breast Carcinoma of No Special Type 33
Infiltrating Ductal Carcinoma of Breast 33
Carcinoma with Apocrine Differentiation 33
Breast Cancer, Male, Susceptibility to 57
Primary Malignant Neoplasm of Breast 71
Microinvasive Carcinoma of Breast 33
Invasive Breast Ductal Carcinoma 16
Susceptibility to Breast Cancer 16
Cancer, Breast, Susceptibility 38
Malignant Tumor of the Breast 11
Breast Cancer Susceptibility 57
Breast Cancer, Familial Male 28
Breast Cancer Familial Male 73
Animal Mammary Neoplasms 71
Neoplasm of Male Breast 11
Familial Breast Cancer 19
Breast Cancer Familial 73
Breast Neoplasms, Male 43
Primary Breast Cancer 11
Breast Male Carcinoma 53
Breast Cancer in Men 19
Carcinoma of Breast 11
Mammary Carcinomas 14
Mammary Neoplasms 71
Mammary Neoplasm 11
Cancer of Breast 42
Breast Neoplasms 43
Breast Neoplasm 16
Mammary Tumors 14
Cancer, Breast 38
Bc 73

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 24-Oct-2022)
Miscellaneous:
genetic heterogeneity


Classifications:



External Ids:

Disease Ontology 11 DOID:1612 DOID:1614 DOID:3459
OMIM® 57 114480
NCIt 49 C4872 C9335
SNOMED-CT via HPO 69 254838004
UMLS 71 C0006142 C0024667 C0238033 more

Summaries for Breast Cancer

MedlinePlus: 41 What is breast cancer? Breast cancer is a cancer that starts in breast tissue. It happens when cells in the breast change and grow out of control. The cells usually form a tumor. Sometimes the cancer does not spread any further. This is called "in situ." If the cancer spreads outside the breast, the cancer is called "invasive." It may just spread to nearby tissues and lymph nodes. Or the cancer may metastasize (spread to other parts of the body) through the lymph system or the blood. Breast cancer is the second most common type of cancer in women in the United States. Rarely, it can also affect men. What are the types of breast cancer? There are different types of breast cancer. The types are based on which breast cells turn into cancer. The types include: Ductal carcinoma, which begins in the cells of the ducts. This is the most common type. Lobular carcinoma, which begins in the lobules. It is more often found in both breasts than other types of breast cancer. Inflammatory breast cancer, in which cancer cells block lymph vessels in the skin of the breast. The breast becomes warm, red, and swollen. This is a rare type. Paget's disease of the breast, which is a cancer involving the skin of the nipple. It usually also affects the darker skin around the nipple. It is also rare. What causes breast cancer? Breast cancer happens when there are changes in the genetic material (DNA). Often, the exact cause of these genetic changes is unknown. But sometimes these genetic changes are inherited, meaning that you are born with them. Breast cancer that is caused by inherited genetic changes is called hereditary breast cancer. There are also certain genetic changes that can raise your risk of breast cancer, including changes in the BRCA1 and BRCA2 genes. These two changes also raise your risk of ovarian and other cancers. Besides genetics, your lifestyle and the environment can affect your risk of breast cancer. Who is at risk for breast cancer? The factors that raise your risk of breast cancer include: Older age History of breast cancer or benign (noncancer) breast disease Inherited risk of breast cancer, including having BRCA1 and BRCA2 gene changes Dense breast tissue A reproductive history that leads to more exposure to the estrogen hormone, including Menstruating at an early age Being at an older age when you first gave birth or never having given birth Starting menopause at a later age Taking hormone therapy for symptoms of menopause Radiation therapy to the breast or chest Obesity Drinking alcohol What are the signs and symptoms of breast cancer? The signs and symptoms of breast cancer include: A new lump or thickening in or near the breast or in the armpit. A change in the size or shape of the breast. A dimple or puckering in the skin of the breast. It may look like the skin of an orange. A nipple turned inward into the breast. Nipple discharge other than breast milk. The discharge might happen suddenly, be bloody, or happen in only one breast. Scaly, red, or swollen skin in the nipple area or the breast Pain in any area of the breast. How is breast cancer diagnosed? Your health care provider may use many tools to diagnose breast cancer and figure out which type you have: A physical exam, including a clinical breast exam (CBE). This involves checking for any lumps or anything else that seems unusual with the breasts and armpits. A medical history. Imaging tests, such as a mammogram, an ultrasound, or an MRI. Breast biopsy. Blood chemistry tests, which measure different substances in the blood, including electrolytes, fats, proteins, glucose (sugar), and enzymes. Some of the specific blood chemistry tests include a basic metabolic panel (BMP), a comprehensive metabolic panel (CMP), and an electrolyte panel. If these tests show that you have breast cancer, you will have tests that study the cancer cells. These tests help your provider decide which treatment would be best for you. The tests may include: Genetic tests for genetic changes such as in the BRCA and TP53 genes. HER2 test. HER2 is a protein involved with cell growth. It is on the outside of all breast cells. If your breast cancer cells have more HER2 than normal, they can grow more quickly and spread to other parts of the body. An estrogen and progesterone receptor test. This test measures the amount of estrogen and progesterone (hormones) receptors in cancer tissue. If there are more receptors than normal, the cancer is called estrogen and/or progesterone receptor positive. This type of breast cancer may grow more quickly. Another step is staging the cancer. Staging involves doing tests to find out whether the cancer has spread within the breast or to other parts of the body. The tests may include other diagnostic imaging tests and a sentinel lymph node biopsy. This biopsy is done to see whether the cancer has spread to the lymph nodes. What are the treatments for breast cancer? Treatments for breast cancer include: Surgery such as A mastectomy, which removes the whole breast A lumpectomy to remove the cancer and some normal tissue around it, but not the breast itself Radiation therapy Chemotherapy Hormone therapy, which blocks cancer cells from getting the hormones they need to grow Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Immunotherapy Can breast cancer be prevented? You may be able to help prevent breast cancer by making healthy lifestyle changes such as: Staying at a healthy weight Limiting alcohol use Getting enough exercisee Limiting your exposure to estrogen by Breastfeeding your babies if you can Limiting hormone therapy If you are at high risk, your health care provider may suggest that you take certain medicines to lower the risk. Some women at very high risk may decide to get a mastectomy (of their healthy breasts) to prevent breast cancer. It's also important to get regular mammograms. They may be able to identify breast cancer in the early stages, when it is easier to treat. NIH: National Cancer Institute

MalaCards based summary: Breast Cancer, also known as breast carcinoma, is related to ovarian cancer and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain, lameness, animal and pain. An important gene associated with Breast Cancer is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are breast carcinoma and Decreased viability

MedlinePlus Genetics: 42 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare. In its early stages, breast cancer usually does not cause pain and may exhibit no noticeable symptoms. As the cancer progresses, signs and symptoms can include a lump or thickening in or near the breast; a change in the size or shape of the breast; nipple discharge, tenderness, or retraction (turning inward); and skin irritation, dimpling, redness, or scaliness. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a person definitely has breast cancer.In some cases, cancerous cells can invade surrounding breast tissue. In these cases, the condition is known as invasive breast cancer. Sometimes, tumors spread to other parts of the body. If breast cancer spreads, cancerous cells most often appear in the bones, liver, lungs, or brain. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.A small percentage of all breast cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary breast cancers tend to develop earlier in life than noninherited (sporadic) cases, and new (primary) tumors are more likely to develop in both breasts.

CDC: 2 Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Breast cancer can begin in different parts of the breast. A breast is made up of three main parts: lobules, ducts, and connective tissue. The lobules are the glands that produce milk. The ducts are tubes that carry milk to the nipple. The connective tissue (which consists of fibrous and fatty tissue) surrounds and holds everything together. Most breast cancers begin in the ducts or lobules. Breast cancer can spread outside the breast through blood vessels and lymph vessels. When breast cancer spreads to other parts of the body, it is said to have metastasized.

Novus Biologicals: 54 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

PubMed Health : 63 Breast cancer: Being diagnosed with breast cancer often comes as a shock at first, and makes people feel very frightened and anxious. Having cancer can really turn your life upside down for a while. It helps to know that if you get breast cancer for the first time and it hasn’t spread far, there’s a good chance that treatment can lead to full recovery. There are also many support services that help people in everyday life, to return to work and cope emotionally with breast cancer.

UniProtKB/Swiss-Prot: 73 A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

OMIM®: 57 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480) (Updated 24-Oct-2022)

GARD: 19 A rare malignant tumor of the breast, affecting mostly older men. It accounts for less than 1% of all malignancies in men. The most common histologic type is invasive ductal carcinoma. Most patients are treated with mastectomy. -- 2004

Disease Ontology 11 Breast cancer: A thoracic cancer that originates in the mammary gland.

Male breast cancer: A breast cancer that occurs in males.

Breast carcinoma: A breast cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia 75 Breast cancer: Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Breast cancer, familial: Hereditary breast-ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal... more...

Male breast cancer: Male breast cancer (MBC) is a cancer in males that originates in their breasts. Males account for less... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ Hereditary Breast Cancer

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2958)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 35.2 TP53 RAD51 PPM1D PIK3CA PALB2 NBN
2 hereditary breast ovarian cancer syndrome 35.1 XRCC3 TP53 RAD54L RAD51 PIK3CA PALB2
3 diffuse gastric and lobular breast cancer syndrome 34.9 TP53 PIK3CA PALB2 KRAS CHEK2 CDH1
4 li-fraumeni syndrome 34.9 TP53 RAD51 PPM1D PIK3CA PALB2 KRAS
5 bilateral breast cancer 34.8 TP53 RAD51 PALB2 ESR1 CHEK2 CDH1
6 hereditary breast cancer 34.6 SLC22A18 RAD54L PPM1D PALB2 CHEK2 CDH1
7 sporadic breast cancer 34.5 TP53 RAD51 PALB2 ESR1 CHEK2 BRIP1
8 bap1 tumor predisposition syndrome 34.5 TP53 PALB2 NBN CHEK2 CDH1 BRIP1
9 estrogen-receptor positive breast cancer 34.3 TP53 PIK3CA ESR1 BRCA2 BRCA1 AKT1
10 lung cancer 34.2 XRCC3 TP53 SLC22A18 RAD51 PIK3CA PALB2
11 colorectal cancer 34.2 XRCC3 TP53 RAD51 PIK3CA PALB2 NBN
12 ductal carcinoma in situ 34.2 TP53 PIK3CA ESR1 CDH1 BRCA2 BRCA1
13 in situ carcinoma 34.2 TP53 PIK3CA KRAS ESR1 CDH1 BRCA2
14 estrogen-receptor negative breast cancer 34.1 TP53 ESR1 CDH1 BRCA2 BRCA1 AKT1
15 breast-ovarian cancer, familial 1 34.0 PALB2 NBN BRIP1 BRCA2 BRCA1
16 inherited cancer-predisposing syndrome 34.0 TP53 PALB2 NBN CHEK2 CDH1 BRIP1
17 female breast cancer 34.0 TP53 ESR1 BRCA2 BRCA1
18 endometrial cancer 33.9 TP53 RAD51 PIK3CA KRAS ESR1 CDH1
19 gastric cancer 33.9 TP53 PIK3CA KRAS ESR1 CHEK2 CDH1
20 breast adenocarcinoma 33.9 TP53 SLC22A18 RB1CC1 PIK3CA KRAS ESR1
21 lynch syndrome 33.8 TP53 RAD51 PIK3CA PALB2 KRAS ESR1
22 adenocarcinoma 33.8 TP53 PIK3CA KRAS CDH1 BRCA2 ATM
23 fanconi anemia, complementation group a 33.7 XRCC3 TP53 RAD54L RAD51 PALB2 NBN
24 breast carcinoma in situ 33.7 TP53 PIK3CA ESR1 CDH1 BRCA2 BRCA1
25 leukemia, acute myeloid 33.7 TP53 RAD51 PIK3CA KRAS ESR1 CHEK2
26 cowden syndrome 33.6 TP53 RAD51 PIK3CA PALB2 KRAS ESR1
27 pancreatic cancer 33.6 TP53 RAD51 PIK3CA PALB2 NBN KRAS
28 prostate cancer 33.6 TP53 RAD51 PIK3CA NBN ESR1 CHEK2
29 premature menopause 33.5 TP53 RAD54L NBN ESR1 CHEK2 BRCA2
30 peripheral nervous system disease 33.4 TP53 KRAS ESR1 CDH1 BRCA1 ATM
31 breast ductal carcinoma 33.4 TP53 RAD54L ESR1 CDH1 BRCA2 BRCA1
32 hypertrophy of breast 33.4 TP53 PIK3CA ESR1 CHEK2 BRCA2 BRCA1
33 breast-ovarian cancer, familial 2 33.3 BRCA2 BRCA1
34 wilms tumor 1 33.3 TP53 SLC22A18 PALB2 KRAS ESR1 CHEK2
35 lobular neoplasia 33.2 TP53 PIK3CA PALB2 ESR1 CDH1 BRCA2
36 ataxia-telangiectasia 33.2 TP53 RAD51 NBN CHEK2 BRCA2 BRCA1
37 aplastic anemia 33.2 XRCC3 TP53 RAD51 PALB2 NBN CHEK2
38 breast disease 33.2 TP53 ESR1 BRCA2 BRCA1
39 colonic benign neoplasm 33.2 TP53 PIK3CA PALB2 KRAS ESR1 CHEK2
40 deficiency anemia 33.1 TP53 RAD51 PALB2 BRIP1 BRCA2 BRCA1
41 breast metaplastic carcinoma 33.1 TP53 ESR1
42 esophageal cancer 33.1 TP53 PIK3CA KRAS ESR1 CHEK2 CDH1
43 comedo carcinoma 33.1 TP53 ESR1 BRCA2
44 ovarian cancer 1 33.0 PALB2 NBN BRIP1 BRCA2 BRCA1
45 xeroderma pigmentosum, variant type 33.0 XRCC3 TP53 RAD54L RAD51 NBN CHEK2
46 breast lobular carcinoma 33.0 TP53 PIK3CA PALB2 ESR1 CDH1 BRCA2
47 apocrine adenocarcinoma 32.9 TP53 PIK3CA ESR1
48 cowden syndrome 1 32.9 TP53 PIK3CA PALB2 CHEK2 BRCA2 BRCA1
49 rhabdomyosarcoma 32.9 TP53 SLC22A18 PIK3CA KRAS ESR1 CHEK2
50 glioblastoma 32.9 TP53 PIK3CA KRAS CDH1 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Human phenotypes related to Breast Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 breast carcinoma 30 HP:0003002

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Neoplasia:
breast carcinoma

Clinical features from OMIM®:

114480 (Updated 24-Oct-2022)

UMLS symptoms related to Breast Cancer:


pelvic pain; lameness, animal; pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.08 KRAS PIK3CA
2 Decreased viability GR00055-A-2 11.08 KRAS PIK3CA
3 Decreased viability GR00055-A-3 11.08 KRAS
4 Decreased viability GR00106-A-0 11.08 KRAS
5 Decreased viability GR00221-A-1 11.08 AKT1 CDH1 ESR1 KRAS PIK3CA
6 Decreased viability GR00221-A-2 11.08 AKT1 ESR1 KRAS PIK3CA CHEK2 BRCA1
7 Decreased viability GR00221-A-3 11.08 AKT1 ATM CHEK2 BRCA1
8 Decreased viability GR00221-A-4 11.08 AKT1 ESR1 PIK3CA ATM CHEK2
9 Decreased viability GR00249-S 11.08 AKT1
10 Decreased viability GR00301-A 11.08 CDH1 KRAS BRCA1
11 Decreased viability GR00342-S-2 11.08 CHEK2
12 Decreased viability GR00381-A-1 11.08 KRAS
13 Decreased viability GR00386-A-1 11.08 ESR1
14 Decreased viability GR00402-S-2 11.08 CDH1 ESR1 PIK3CA
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.77 BARD1 BRCA1 BRCA2 NBN PALB2 RAD54L
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.77 ATM BRCA1 BRCA2 BRIP1 PALB2 PPM1D
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.77 ATM BARD1 BRCA1 BRCA2 CHEK2 NBN
18 Decreased homologous recombination repair frequency GR00151-A-1 10.37 BARD1 BRCA1 RAD51
19 Decreased homologous recombination repair frequency GR00151-A-2 10.37 BRCA1 RAD51
20 Decreased homologous recombination repair frequency GR00236-A-1 10.37 BARD1 BRCA1 BRCA2 PALB2 RAD51
21 Decreased homologous recombination repair frequency GR00236-A-2 10.37 BARD1 BRCA1 BRCA2 PALB2 RAD51
22 Decreased homologous recombination repair frequency GR00236-A-3 10.37 BARD1 BRCA1 BRCA2 PALB2 RAD51
23 no effect GR00402-S-1 10.14 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
24 no effect GR00402-S-2 10.14 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.1 CHEK2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.1 RB1CC1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.1 CHEK2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.1 CHEK2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.1 TP53
30 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.1 CHEK2 KRAS RB1CC1 TP53
31 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.1 CHEK2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.1 TP53
33 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.1 CHEK2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.1 TP53
35 Increased shRNA abundance (Z-score > 2) GR00366-A-171 10.1 RB1CC1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.1 RB1CC1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.1 TP53
38 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.1 TP53
39 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.1 TP53
40 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.1 TP53
41 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.1 KRAS
42 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.1 TP53
43 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.1 RB1CC1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.1 TP53
45 Increased shRNA abundance (Z-score > 2) GR00366-A-59 10.1 RB1CC1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.1 CHEK2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.1 TP53
48 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.1 KRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.1 CHEK2
50 Synthetic lethal with cisplatin GR00101-A-1 9.91 BARD1 BRCA1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
2 neoplasm MP:0002006 10.43 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
3 growth/size/body region MP:0005378 10.42 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
4 nervous system MP:0003631 10.38 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
5 cellular MP:0005384 10.36 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
6 endocrine/exocrine gland MP:0005379 10.35 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
7 embryo MP:0005380 10.33 AKT1 ATM BARD1 BRCA1 BRCA2 CDH1
8 normal MP:0002873 10.2 AKT1 BARD1 BRCA1 BRCA2 CDH1 ESR1
9 immune system MP:0005387 10.17 AKT1 ATM BRCA1 BRCA2 CDH1 CHEK2
10 muscle MP:0005369 10.13 AKT1 BRCA1 ESR1 KRAS NBN PIK3CA
11 reproductive system MP:0005389 10.13 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
12 cardiovascular system MP:0005385 10.11 AKT1 ATM BRCA1 CDH1 CHEK2 ESR1
13 digestive/alimentary MP:0005381 10.03 BRCA1 BRCA2 CDH1 ESR1 KRAS PIK3CA
14 hematopoietic system MP:0005397 10 AKT1 ATM BRCA1 BRCA2 BRIP1 CHEK2
15 mortality/aging MP:0010768 9.91 AKT1 ATM BARD1 BRCA1 BRCA2 CDH1
16 integument MP:0010771 9.4 AKT1 ATM BRCA1 BRCA2 CDH1 ESR1

Drugs & Therapeutics for Breast Cancer

PubMed Health treatment related to Breast Cancer: 63

The treatment options always depend on the type and size of the tumor , where it has spread to (if it has spread), the patient’s general health, as well as their personal preferences. Breast cancer can be treated with surgery , radiation and medication. Different treatment approaches are often combined. The standard treatment is to try to surgically remove as much of the tumor as possible. Neighboring lymph nodes are sometimes also removed. If the tumor is small, women are often faced with a decision: Should they keep the breast or have it completely removed? Nowadays many women can have surgery that allows them to keep the breast (breast-conserving surgery). But sometimes the entire breast needs to be removed (mastectomy ) to make sure that all of the tumor tissue has gone. Chemotherapy (treatment with medication) is sometimes used to shrink larger tumors before surgery and make it easier to operate on them. This kind of treatment is called “neoadjuvant chemotherapy.” Chemotherapy is sometimes used after surgery too. Women who have a hormone -sensitive tumor may have anti-hormonal therapy . This aims to slow down tumor growth. After breast -conserving surgery the surrounding tissue is exposed to radiation, if possible, so that any remaining tumor cells can be destroyed. This is sometimes necessary after a mastectomy as well. Radiotherapy is also commonly used if the tumor cannot be surgically removed. The different types of treatment can be very difficult to go through and sometimes have very severe side effects or cause other medical problems. The side effects vary depending on the kind of treatment, but they are often easy to treat. The treatment of side effects is part of what is known as supportive care. Before deciding on whether to have a particular treatment , there is usually enough time to get information from your doctor about the possible benefits and the expected side effects, and to talk with your family or other people who are close to you. You have the right to seek a second opinion from another doctor or to decide not to have a treatment.

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 1082, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Iron Approved Phase 4 7439-89-6 29936
7
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
8
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
9
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
13
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
14
Fosaprepitant Approved Phase 4 172673-20-0 219090 135413538
15
Crofelemer Approved Phase 4 33507-63-0, 148465-45-6 36511 44359816
16
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 135413536
17
Lactulose Approved Phase 4 4618-18-2 11333
18
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
19
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
20
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
21
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
22
Haloperidol Approved Phase 4 52-86-8 3559
23
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
24
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
25
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
26
Povidone-iodine Approved Phase 4 25655-41-8
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Sultamicillin Approved, Investigational Phase 4 76497-13-7 2175
29
Sulbactam Approved Phase 4 68373-14-8 5316
30
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
31
Succinylcholine Approved Phase 4 306-40-1, 71-27-2 5314
32
Desflurane Approved Phase 4 57041-67-5 42113
33
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
34
Zoledronic acid Approved Phase 4 118072-93-8 68740
35
Denosumab Approved Phase 4 615258-40-7
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Pamidronic acid Approved Phase 4 40391-99-9 4674
38
Esketamine Approved, Investigational Phase 4 33643-46-8 182137
39
Tioguanine Approved Phase 4 154-42-7 2723601
40
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
41
Thrombin Approved, Investigational Phase 4
42
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
43
Tranexamic acid Approved Phase 4 1197-18-8 5526
44
Follitropin Approved, Vet_approved Phase 4 97048-13-0, 146479-72-3, 9002-68-0 62819
45
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
46
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
47
Palbociclib Approved, Investigational Phase 4 571190-30-2 5330286
48
Fulvestrant Approved, Investigational Phase 4 129453-61-8 17756771 104741
49
Norepinephrine Approved Phase 4 51-41-2 439260
50
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
51
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
52
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 2052-63-3, 22737-97-9, 22737-96-8, 68-26-8 9904001 9947823 5280382 445354
53
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
54
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
55
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
56
Rivoceranib Investigational Phase 4 811803-05-1 11315474
57
Phenothiazine Experimental, Vet_approved Phase 4 92-84-2 7108
58
Alizapride Investigational Phase 4 59338-93-1 43008
59
Ramosetron Investigational Phase 4 132036-88-5 4442 108000
60
Maleic acid Experimental, Investigational Phase 4 110-16-7, 110-17-8 444266 444972
61
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 4 461-06-3
62 glucocorticoids Phase 4
63 Cholinergic Agents Phase 4
64 Neuroprotective Agents Phase 4
65
Methylprednisolone Acetate Phase 4 584547
66 Retinol palmitate Phase 4
67 Chaste Tree Phase 4
68 Cardiac Glycosides Phase 4
69
abobotulinumtoxinA Phase 4
70 Botulinum Toxins, Type A Phase 4
71 Botulinum Toxins Phase 4
72 Dermatologic Agents Phase 4
73 Gastrointestinal Agents Phase 4
74 Cytochrome P-450 Enzyme Inhibitors Phase 4
75 Antiemetics Phase 4
76 Immunosuppressive Agents Phase 4
77
Triamcinolone hexacetonide Phase 4
78
Triamcinolone diacetate Phase 4
79
Triamcinolone Acetonide Phase 4 6436
80 Antipsychotic Agents Phase 4
81 Cardiotonic Agents Phase 4
82
Imatinib Mesylate Phase 4 220127-57-1
83 Excitatory Amino Acid Antagonists Phase 4
84 Neurokinin-1 Receptor Antagonists Phase 4
85
Neurokinin A Phase 4 86933-74-6 55582
86 Emetics Phase 4
87
Haloperidol decanoate Phase 4 52919
88 Anesthetics, Dissociative Phase 4
89 Viscum album peptide Phase 4
90 Dexamethasone 21-phosphate Phase 4
91 beta-Lactamase Inhibitors Phase 4
92 Blood Substitutes Phase 4
93 Plasma Substitutes Phase 4
94 Disinfectants Phase 4
95 Silymarin Phase 4
96 Trastuzumab biosimilar HLX02 Phase 4
97 Tea Phase 4
98 Pharmaceutical Solutions Phase 4
99 Hemostatics Phase 4
100 Coagulants Phase 4
101 Anesthetics, General Phase 4
102 Platelet Aggregation Inhibitors Phase 4
103 Anesthetics, Intravenous Phase 4
104 Superoxide Dismutase Phase 4
105 Gotu Kola Phase 4
106 Anesthetics, Inhalation Phase 4
107 Antifibrinolytic Agents Phase 4
108 Vitamin B6 Phase 4
109 Vitamin B 6 Phase 4
110 Betamethasone-17,21-dipropionate Phase 4
111
Betamethasone Valerate Phase 4 2152-44-5
112
Betamethasone sodium phosphate Phase 4
113
Betamethasone benzoate Phase 4
114 Thiamin Phase 4
115 Vitamin B1 Phase 4
116 Fibrin Tissue Adhesive Phase 4
117 Follicle Stimulating Hormone Phase 4
118
Angiotensinogen Phase 4 16133225
119 Angiotensin Receptor Antagonists Phase 4
120 Angiotensin II Type 1 Receptor Blockers Phase 4
121 Giapreza Phase 4
122 Sacubitril and valsartan sodium hydrate drug combination Phase 4
123 Hypnotics and Sedatives Phase 4
124 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
125 Adrenergic Agents Phase 4
126 Adrenergic alpha-Agonists Phase 4
127 Adrenergic Agonists Phase 4
128
Desvenlafaxine Succinate Phase 4 386750-22-7
129
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
130
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
131
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
132
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
133
Diclofenac Approved, Vet_approved Phase 3 15307-86-5, 15307-79-6 3033
134
Famotidine Approved Phase 3 76824-35-6 3325 5702160
135
Histamine Approved, Investigational Phase 3 51-45-6 774
136
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
137
Calcium carbonate Approved, Investigational Phase 3 471-34-1
138
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
139
Lithium carbonate Approved Phase 3 554-13-2
140
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 10631 6279
141
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
142
BCG vaccine Approved, Investigational Phase 3
143
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 596 6253 6175
144
Duloxetine Approved Phase 3 136434-34-9, 116539-59-4 60835
145
Citalopram Approved Phase 3 59729-32-7, 59729-33-8 2771
146
Tibolone Approved, Investigational Phase 3 5630-53-5 5470 444008
147
Raloxifene Approved, Investigational Phase 3 82640-04-8, 84449-90-1 5035
148
Candesartan cilexetil Approved Phase 3 145040-37-5
149
Norethisterone Approved Phase 3 68-22-4 199472 6230
150
Donepezil Approved Phase 3 120014-06-4 3152
151
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
152
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
153
Lanreotide Approved Phase 3 108736-35-2 71349 6918011
154
Mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7 4240 441336
155
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
156
Mepivacaine Approved, Vet_approved Phase 3 96-88-8, 1722-62-9 4062
157
Acetylcarnitine Approved, Investigational Phase 3 3040-38-8
158
Telbivudine Approved, Investigational Phase 3 3424-98-4 159269
159
Cetirizine Approved Phase 3 83881-51-0 2678
160
Clindamycin Approved, Vet_approved Phase 3 18323-44-9, 24729-96-2 29029
161
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
162
Reviparin Approved, Investigational Phase 3 9041-08-1
163
Aminoglutethimide Approved, Investigational Phase 3 125-84-8 2145
164
Pilocarpine Approved, Investigational Phase 3 54-71-7, 92-13-7 4819 5910
165
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
166
Ofloxacin Approved Phase 3 82419-36-1 4583
167
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
168
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
169
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
170
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
171
Ichthammol Approved Phase 2, Phase 3 8029-68-3
172
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
173
Pertuzumab Approved Phase 3 380610-27-5
174
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
175
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
176
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
177
Simvastatin Approved Phase 3 79902-63-9 54454
178
Palonosetron Approved, Investigational Phase 3 119904-90-4, 135729-56-5 148211 6337614
179
Memantine Approved, Investigational Phase 3 41100-52-1, 19982-08-2 4054
180
Olanzapine Approved, Investigational Phase 3 132539-06-1 135398745 4585
181
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
182
Magnesium sulfate Approved, Investigational, Vet_approved Phase 2, Phase 3 7487-88-9
183
Tropisetron Approved, Investigational Phase 3 105826-92-4, 89565-68-4 656665
184
Simethicone Approved Phase 2, Phase 3 8050-81-5
185
Belladonna Approved, Experimental Phase 3
186
Pravastatin Approved Phase 3 81093-37-0 54687
187
Aminolevulinic acid Approved Phase 3 106-60-5 137
188
Prochlorperazine Approved, Vet_approved Phase 3 1984-02-6, 58-38-8 4917
189
Daunorubicin Approved Phase 3 20830-81-3 30323
190
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
191
Margetuximab Approved, Investigational Phase 3 1350624-75-7
192
Capsaicin Approved Phase 3 404-86-4 1548943
193
Bisoprolol Approved Phase 3 66722-44-9 2405
194
Ramipril Approved Phase 3 87333-19-5 5362129
195 Barley Approved Phase 3
196
Olaparib Approved Phase 3 763113-22-0 23725625
197
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
198
Alitretinoin Approved, Investigational Phase 3 5300-03-8 449171
199
Pitavastatin Approved Phase 2, Phase 3 147511-69-1 5282452
200
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
201
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030
202
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
203
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
204
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
205
Sunitinib Approved, Investigational Phase 3 557795-19-4 5329102
206
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
207
Polyestradiol phosphate Approved Phase 3 28014-46-2
208
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
209
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
210
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
211
Ethinylestradiol Approved Phase 3 57-63-6 5991
212
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
213 Orange Approved Phase 3
214
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
215
Eplerenone Approved Phase 2, Phase 3 107724-20-9 443872
216
(R)-Bicalutamide Approved, Experimental Phase 3 90357-06-5, 113299-40-4 2375
217
Esomeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6, 119141-88-7 9568614 4594
218
Carmustine Approved, Investigational Phase 3 154-93-8 2578
219
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 55-31-2, 114-07-8 12560
220
Cycloserine Approved Phase 3 68-41-7 6234
221
Asparaginase Escherichia coli Approved, Investigational Phase 2, Phase 3 9015-68-3
222
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
223
Lorazepam Approved Phase 3 846-49-1 3958
224
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
225
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 3 8001-79-4 96919
226
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
227
Isotretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4, 4759-48-2 5538 444795 5282379
228
Melatonin Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 73-31-4 896
229
Iniparib Investigational Phase 3 160003-66-7 9796068
230
Etirinotecan pegol Investigational Phase 3 848779-32-8 71300725
231
Dexetimide Withdrawn Phase 3 21888-98-2 30843
232
Candesartan Experimental Phase 3 139481-59-7 2541
233
Boron Experimental Phase 3 7440-42-8 5460517
234
Efaproxiral Investigational Phase 3 131179-95-8 122335
235
Carnosine Experimental, Investigational Phase 3 305-84-0, 107667-60-7 439224
236
Marimastat Investigational Phase 3 154039-60-8 119031
237
Sinomenine Investigational Phase 3 115-53-7 416119
238
Black cohosh Experimental Phase 3
239
Afimoxifene Investigational Phase 2, Phase 3 68392-35-8 63062
240
Camptothecin Experimental Phase 3 7689-03-4 24360
241
Diethyl ether Experimental Phase 3 60-29-7 3283
242
Chitosan low molecular weight (20-200 mpa.s) Experimental Phase 3 14257-69-3, 9012-76-4 441477 71853
243
Fenretinide Investigational Phase 3 65646-68-6 5288209
244
Atamestane Investigational Phase 3 96301-34-7 13371250 57050
245 Endostar protein Phase 3
246 Rue Phase 3
247 Anti-Ulcer Agents Phase 3
248
Histamine phosphate Phase 3 51-74-1 134614
249 Histamine H1 Antagonists Phase 3
250 Histamine Antagonists Phase 3
251 Anti-Allergic Agents Phase 3
252 Antacids Phase 3
253
Megestrol Phase 3 3562-63-8 3080587 19090
254 Muscarinic Antagonists Phase 3
255 Parasympatholytics Phase 3
256 Cholinergic Antagonists Phase 3
257 Micronutrients Phase 3
258 Calciferol Phase 3
259 Vitamins Phase 3
260 Trace Elements Phase 3
261 Phytoestrogens Phase 2, Phase 3
262 Contraceptive Agents, Male Phase 3
263 Progestins Phase 3
264 Interferon-gamma Phase 3
265 3,4-dihydroxyphenylethanol Phase 2, Phase 3
266 Antiparkinson Agents Phase 3
267 Diphosphonates Phase 3
268 Flax Phase 3
269 Castor Phase 3
270 Nootropic Agents Phase 3
271
Norethindrone Acetate Phase 3 541197
272 Cholinesterase Inhibitors Phase 3
273 Histamine H1 Antagonists, Non-Sedating Phase 3
274 Calcium Supplement Phase 3
275 Plasminogen Activator Inhibitor 1 Phase 3
276 Caseins Phase 2, Phase 3
277 Caproate Phase 2, Phase 3
278
2,2'-dithiodiethanesulfonic acid Phase 3 65626
279 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
280 Detox adjuvant Phase 3
281 Keyhole-limpet hemocyanin Phase 3
282
Clindamycin phosphate Phase 3 32603
283 Clindamycin palmitate Phase 3
284 Shark Cartilage Phase 3
285 Calcium heparin Phase 3
286
Ginkgo Phase 3
287 Heparin, Low-Molecular-Weight Phase 3
288 Pirinitramide Phase 3
289 Muscarinic Agonists Phase 3
290 Gentamicins Phase 3
291 Mandelic Acids Phase 3
292 BB 1101 Phase 3
293
protease inhibitors Phase 3
294 HIV Protease Inhibitors Phase 3
295 Taxane Phase 3 108169
296 Antimetabolites Phase 3
297 Antineoplastic Agents, Alkylating Phase 2, Phase 3
298 Antibiotics, Antitubercular Phase 2, Phase 3
299 Alkylating Agents Phase 2, Phase 3
300
Rosuvastatin Calcium Phase 3 147098-20-2
301 Prolactin Release-Inhibiting Factors Phase 3
302 Antipyretics Phase 3
303 Fibrinolytic Agents Phase 3
304 Adrenergic alpha-Antagonists Phase 3
305 Adrenergic alpha-1 Receptor Antagonists Phase 3
306 Dopamine Antagonists Phase 3
307 Phytosterol Phase 3
308 Folate Phase 2, Phase 3
309 Vitamin B9 Phase 2, Phase 3
310 Vitamin B Complex Phase 2, Phase 3
311 Diketopiperazines Phase 3
312 Angiotensin-Converting Enzyme Inhibitors Phase 3
313 Contraceptives, Postcoital Phase 3
314 Keratolytic Agents Phase 3
315 Halichondrin B Phase 3 5915307
316 Immunoglobulins, Intravenous Phase 3
317 Anti-Bacterial Agents Phase 3
318 Dopamine Uptake Inhibitors Phase 3
319 Dopamine Agents Phase 3
320 Contraceptives, Oral, Hormonal Phase 3
321 Contraceptives, Oral Phase 3
322 Contraceptive Agents Phase 3
323 Central Nervous System Stimulants Phase 3
324 Antifungal Agents Phase 3
325
Triptorelin Pamoate Phase 3
326 Mineralocorticoids Phase 2, Phase 3
327 Anticonvulsants Phase 3
328 Estradiol 3-benzoate Phase 3
329 Estradiol 17 beta-cypionate Phase 3
330 17 alpha-Hydroxyprogesterone Caproate Phase 3
331 11-hydroxyprogesterone Phase 3
332
Razoxane Phase 3
333 Hematinics Phase 3
334 Androgen Antagonists Phase 3
335
Epoetin Alfa Phase 3
336 GABA Modulators Phase 3
337 Contraceptives, Oral, Combined Phase 3
338 Norgestimate, ethinyl estradiol drug combination Phase 3
339 calcium channel blockers Phase 3
340 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
341 diuretics Phase 2, Phase 3
342 Chrysarobin Phase 3
343 Tocolytic Agents Phase 3
344 Erythromycin stearate Phase 2, Phase 3
345 Erythromycin Ethylsuccinate Phase 2, Phase 3
346 Erythromycin Estolate Phase 2, Phase 3
347
Cetrorelix Approved, Investigational Phase 2 120287-85-6 25074887
348
Altretamine Approved Phase 2 645-05-6 2123
349
Ganirelix Approved Phase 1, Phase 2 124904-93-4 44208957 16186319 16130966
350
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
351
Tirbanibulin Approved, Investigational Phase 1, Phase 2 897016-82-9 23635314
352
Cianidanol Approved, Withdrawn Phase 2 154-23-4 9064
353
Denileukin diftitox Approved, Investigational Phase 1, Phase 2 173146-27-5
354
Methylthioninium Approved, Experimental, Investigational Phase 2 61-73-4, 7060-82-4 6099
355
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
356
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
357
Aflibercept Approved Phase 2 862111-32-8 124490314
358
Chlorhexidine Approved, Vet_approved Phase 2 55-56-1 2713 9552079
359
Pirfenidone Approved, Investigational Phase 1, Phase 2 53179-13-8 40632
360
Fluocinonide Approved, Investigational Phase 2 356-12-7 9642
361
Ethanol Approved Phase 2 64-17-5 702
362
Curcumin Approved, Investigational Phase 2 458-37-7, 84765-67-3 969516
363
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
364
Naproxen Approved, Vet_approved Phase 2 22204-53-1 156391 1302
365
Ketoconazole Approved, Investigational Phase 2 65277-42-1, 142128-57-2 47576 3823 638701
366
Chloroquine Approved, Investigational, Vet_approved Phase 2 54-05-7 2719
367
Nimesulide Approved, Investigational, Withdrawn Phase 2 51803-78-2 4495
368
Etoposide Approved Phase 2 33419-42-0 36462
369
Bexarotene Approved, Investigational Phase 2 153559-49-0 82146
370
Calcipotriol Approved Phase 2 112965-21-6 5288783
371
Lenalidomide Approved Phase 2 191732-72-6 216326
372
Pantoprazole Approved Phase 2 102625-70-7, 138786-67-1 4679
373
Pixantrone Approved, Investigational Phase 2 144510-96-3 134019
374
Neostigmine Approved, Vet_approved Phase 2 59-99-4 4456 5824
375
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
376 Mango Approved Phase 2
377
Estrone Approved Phase 1, Phase 2 53-16-7 5870
378
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
379
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
380
Selenious acid Approved, Investigational Phase 2 14124-67-5, 7783-00-8 1091
381
Amlodipine Approved Phase 1, Phase 2 88150-42-9 2162
382
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
383
Cocaine Approved, Illicit Phase 2 50-36-2 446220 5760
384
Lisinopril Approved, Investigational Phase 2 83915-83-7, 76547-98-3 5362119
385
Etoricoxib Approved, Investigational Phase 2 202409-33-4 123619
386
Budesonide Approved Phase 2 51333-22-3 5281004 40000 63006
387
Colestipol Approved Phase 2 26658-42-4 62816
388
Magnesium oxide Approved Phase 2 1309-48-4 14792
389
Mercaptopurine Approved Phase 2 50-44-2 667490
390
Daratumumab Approved Phase 1, Phase 2 945721-28-8
391
Oprelvekin Approved, Investigational Phase 2 145941-26-0
392
Methadone Approved Phase 1, Phase 2 76-99-3, 1095-90-5 4095
393
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
394
Mycophenolic acid Approved, Investigational Phase 1, Phase 2 24280-93-1 446541
395
Amitriptyline Approved Phase 2 50-48-6 2160
396
Adenosine Approved, Investigational Phase 2 58-61-7 60961
397
Rifaximin Approved, Investigational Phase 2 80621-81-4 46783403 6436173
398
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
399
Gemcitabine Approved Phase 1, Phase 2 95058-81-4, 122111-03-9 60750
400
Pancrelipase Approved, Investigational Phase 2 53608-75-6 8519
401
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
402
Fluorouracil Approved Phase 2 51-21-8 3385
403
Canagliflozin Approved Phase 2 842133-18-0 74323022 24812758
404
Bazedoxifene Approved, Investigational Phase 2 198481-32-2 154257
405
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
406
Methoxsalen Approved Phase 2 298-81-7 4114
407
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
408
Dapagliflozin Approved Phase 2 461432-26-8 9887712
409
Cephalexin Approved, Investigational, Vet_approved Phase 2 15686-71-2 27447
410
Rituximab Approved Phase 1, Phase 2 174722-31-7
411
Sulfasalazine Approved Phase 2 599-79-1 5353980 5339 5359476
412
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
413
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
414
Phenobarbital Approved, Investigational Phase 1, Phase 2 50-06-6 4763
415
Trametinib Approved Phase 2 871700-17-3 11707110
416
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
417
Clonidine Approved Phase 2 4205-91-8, 4205-90-7 2803 20179
418
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
419
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
420
Hydrogen peroxide Approved, Vet_approved Phase 2 7722-84-1 784
421
Sulindac Approved, Investigational Phase 2 38194-50-2 5352 1548887
422
Disulfiram Approved Phase 2 97-77-8 3117
423
Cilostazol Approved, Investigational Phase 1, Phase 2 73963-72-1 2754
424
Deferoxamine Approved, Investigational Phase 2 70-51-9 2973
425
Perindopril Approved Phase 2 82834-16-0, 107133-36-8 107807
426
Telmisartan Approved, Investigational Phase 2 144701-48-4 65999
427
Eflornithine Approved, Withdrawn Phase 1, Phase 2 70052-12-9 3009
428
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
429
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
430
Teriflunomide Approved Phase 1, Phase 2 108605-62-5, 163451-81-8 54677977 54684141
431
Leflunomide Approved, Investigational Phase 1, Phase 2 75706-12-6 3899
432
Osimertinib Approved Phase 2 1421373-65-0 71496458
433
Lomustine Approved, Investigational Phase 1, Phase 2 13010-47-4 3950
434
Promethazine Approved, Investigational Phase 1, Phase 2 60-87-7 4927
435
Diphenhydramine Approved, Investigational Phase 1, Phase 2 147-24-0, 58-73-1 3100
436
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
437
Progesterone Approved, Vet_approved Phase 1, Phase 2 57-83-0 5994
438
Minocycline Approved, Investigational Phase 2 10118-90-8, 13614-98-7 54675783 5281021
439
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 3640 5754
440
Hydrocortisone succinate Approved Phase 2 2203-97-6 3643
441
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
442
Lactitol Approved, Investigational Phase 2 585-86-4, 585-88-6 157355 493591
443
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 6473866 445643
444
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
445
Caffeine Approved Phase 2 58-08-2 2519
446
Epitestosterone Approved, Experimental, Investigational Phase 2 481-30-1, 58-22-0 5408 10204 6013
447
Acyclovir Approved Phase 2 59277-89-3 2022
448
Valaciclovir Approved, Investigational Phase 2 124832-27-5, 124832-26-4 60773 135398742
449
Vinblastine Approved Phase 2 865-21-4 241903 13342
450
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
451
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
452
Futibatinib Approved, Investigational Phase 1, Phase 2 1448169-71-8 71621331
453
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
454
Infigratinib Approved, Investigational Phase 2 872511-34-7 53235510
455
Coal tar Approved Phase 2 8007-45-2
456
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
457
Hydroquinone Approved, Investigational Phase 2 123-31-9 785
458
Vemurafenib Approved Phase 2 918504-65-1 42611257
459
Lutetium Lu 177 dotatate Approved, Investigational Phase 2 437608-50-9 76966897
460
Losartan Approved Phase 2 114798-26-4 3961
461
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 9812710 6427057
462
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
463
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
464
Atorvastatin Approved Phase 2 134523-00-5 60823
465
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
466
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
467
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0 21873174 65157
468
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
469
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
470
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
471
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
472
Nicotine Approved Phase 2 54-11-5 942 89594
473
Trastuzumab Approved, Investigational Phase 2 180288-69-1
474
Tucatinib Approved, Investigational Phase 1, Phase 2 937263-43-9 51039094
475
Nivolumab Approved Phase 1, Phase 2 946414-94-4
476
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
477
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1
478
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
479
Panitumumab Approved, Investigational Phase 2 339177-26-3
480
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
481
Lenograstim Approved, Investigational Phase 2 135968-09-1
482
Vinorelbine Approved, Investigational Phase 1, Phase 2 71486-22-1 44424639 60780
483
Loperamide Approved Phase 2 53179-11-6 3955
484
Melphalan Approved Phase 2 148-82-3 4053 460612
485
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
486
Goserelin Approved Phase 2 65807-02-5 5311128 47725
487
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
488
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
489
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
490
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
491
Metronidazole Approved Phase 1, Phase 2 443-48-1, 69198-10-3 4173
492
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181
493
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
494
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239
495
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
496
Copper Approved, Investigational Phase 2 7440-50-8 27099
497
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
498
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
499
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
500
Panobinostat Approved, Investigational Phase 1, Phase 2 40495